Trials / Completed
CompletedNCT02117648
A Study of LY2835219 in Participants With Cancer
Effects of CYP3A Inhibition by Clarithromycin on the Pharmacokinetics of LY2835219 and Its Metabolites in Cancer Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety and tolerability of these drugs will be studied. Each participant will complete 2 study periods in fixed order. After screening, Period 1 will last approximately 8 days and Period 2 will last approximately 15 days. Participants who complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation criteria are met.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Administered orally |
| DRUG | Clarithromycin | Administered orally |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-02-01
- Completion
- 2015-08-01
- First posted
- 2014-04-21
- Last updated
- 2019-01-07
- Results posted
- 2018-08-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02117648. Inclusion in this directory is not an endorsement.